Cypress Capital Management LLC WY Holds Position in Johnson & Johnson (NYSE:JNJ)
Cypress Capital Management LLC WY maintained its position in shares of Johnson & Johnson (NYSE:JNJ) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,522 shares of the company’s stock at the end of the first quarter. Johnson & Johnson comprises approximately 0.9% of Cypress Capital Management LLC WY’s portfolio, making the stock its 27th largest position. Cypress Capital Management LLC WY’s holdings in Johnson & Johnson were worth $688,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp raised its stake in Johnson & Johnson by 3.3% in the fourth quarter. State Street Corp now owns 153,566,950 shares of the company’s stock valued at $17,692,455,000 after buying an additional 4,892,277 shares during the last quarter. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $3,220,322,000. Macquarie Group Ltd. raised its stake in Johnson & Johnson by 5.6% in the fourth quarter. Macquarie Group Ltd. now owns 6,851,198 shares of the company’s stock valued at $789,328,000 after buying an additional 362,616 shares during the last quarter. Bank of Montreal Can raised its stake in Johnson & Johnson by 0.4% in the first quarter. Bank of Montreal Can now owns 6,837,755 shares of the company’s stock valued at $851,642,000 after buying an additional 26,606 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Johnson & Johnson by 4.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,417,794 shares of the company’s stock valued at $739,409,000 after buying an additional 280,008 shares during the last quarter. Hedge funds and other institutional investors own 66.06% of the company’s stock.
Johnson & Johnson (JNJ) traded down 0.24% on Monday, reaching $132.86. 2,953,688 shares of the company traded hands. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The stock has a 50 day moving average of $133.33 and a 200-day moving average of $125.48. The stock has a market capitalization of $357.90 billion, a price-to-earnings ratio of 22.48 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the business posted $1.74 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
COPYRIGHT VIOLATION WARNING: “Cypress Capital Management LLC WY Holds Position in Johnson & Johnson (NYSE:JNJ)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/07/johnson-johnson-nysejnj-position-maintained-by-cypress-capital-management-llc-wy-updated-updated-updated.html.
JNJ has been the subject of several recent analyst reports. Barclays PLC reaffirmed an “equal weight” rating and issued a $130.00 target price (up from $125.00) on shares of Johnson & Johnson in a report on Monday, April 17th. BTIG Research reissued a “hold” rating on shares of Johnson & Johnson in a report on Wednesday, April 19th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 price objective for the company in a report on Monday, April 24th. Jefferies Group LLC reissued a “hold” rating and set a $135.00 price objective (down from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. Finally, J P Morgan Chase & Co raised shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $123.64 to $140.00 in a report on Monday, May 15th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $133.72.
In related news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.